A conservation retreat near Machynlleth has banned vaccinated visitors as a “precaution”, claiming that people who have had the coronavirus jab could have “an effect” on the unvaccinated.
Blaeneinion, a 75-acre conservation project at the head of the Artists Valley which has cottages on site for people to visit the wildlife, walks and activities on site, has taken the step to ban anyone who has received the vaccine from staying despite the overwhelming scientific evidence that the vaccine is safe and effective.
The retreat claimed that vaccinated people cause “reactions” in the unvaccinated.
The retreat said it has had an “unexpected and overwhelming outpouring of support” since announcing its decision and are now “fully booked until September.”
“With great sadness we have made the decision that we will be unable to welcome folk on site that are ‘vaccinated’ with the experimental Covid-19 jab,” the retreat said on its website. “Significant reports are emerging of effects on unvaccinated people simply spending time around the ‘vaccinated’.
“As you may be aware, the Covid-19 injections are experimental - they are unlike any other previous vaccines and contain a new mRNA technology that causes our own immune systems to manufacture spike proteins.
“Anyone participating in the ‘vaccination’ program are involved in a clinical trial.
“It would appear that these spike proteins can be exhaled or excreted through the skin and are triggering reactions in folk around them who have not been injected.”
“As this is a rapidly emerging and previously unknown situation, we feel that the precautionary principle is best adopted until more is known.”
The retreat added that it has a “duty of care to our staff and to anyone staying on site.”
“In addition, it has become clear that anyone participating in this clinical trial invalidates their life insurance policy and our own Public Liability cover does not cover people who have volunteered for medical experiments should they fall ill or injure themselves on site,” the retreat added.







Comments
This article has no comments yet. Be the first to leave a comment.